This systematic review of psychological therapies for borderline personality disorder (BPD), conducted in Spain, takes an interesting approach to reviewing the literature. Unfortunately, there appear to have been challenges in translating the systematic review from Spanish and the text can be difficult to follow at times. This is a real shame as it is an [read the full story…]
Varenicline is a prescription drug to help people stop smoking that works by stimulating the nicotine receptors in the brain to reduce cravings and decrease the pleasure that results from smoking. Quit attempts aided by varenicline are up to 2-3 times more successful than those without (Cahill et al 2009 and 2012). However, following the [read the full story…]
Bipolar disorder is an affective disorder marked by cycles between mania and depression. It has an early onset, with mean age ranging from 19 to 29 (Offord, 2012) and a prevalence of 0.5% – 4.3% in primary care alone, stretching to 9.3% in some settings (Cerimele, Chwastiak, Dodson, & Katon, 2013). With its problematic recurring [read the full story…]
Attention Deficit Hyperactivity Disorder (ADHD) is a developmental neurological condition affecting functioning in a number of domains, but in particular, the ability to focus and concentrate, and regulate activity levels. This is a common disorder with 2.5-4.0% of adults meeting diagnostic criteria for ADHD (Fayyad et al, 2007), and this condition has significant impact on a persons [read the full story…]
There is a high rate of co-morbidity between depression and smoking; rates of smoking are approximately double in those with depression compared with the general population. In addition, smokers with depression tend to have higher rates of nicotine dependence, suffer greater negative affect during abstinence/withdrawal, are more likely to fail in quit attempts, and are [read the full story…]
Having a life threatening disease such as cancer and undergoing gruelling treatment can have detrimental psychological effects. According to a recent review, for instance, the prevalence of depression among cancer patients is 10.8%, when assessed by a standardised clinical assessment (Ng et al. 2011). The authors of this meta-analysis make the argument that established criteria [read the full story…]
Cannabis is the second most commonly used recreational drug, after alcohol, in the UK. The number of regular users has risen considerably over the past decade, and this has been particularly apparent in the adolescent population. With this rise there have been concerns about the long term consequences of heavy cannabis use. Cannabis use has [read the full story…]
Many of our older readers will remember tales of the Great Elf Mother running miles every day, o’er hills and vales, to bring the very latest evidence-based research to us younger elves at the breakfast table. It was she who inspired our National Elf Service, and I’m delighted to say that she’s still going strong [read the full story…]
Major depression remains a serious condition that often proves refractory to pharmacological or psychotherapeutic interventions. Because depression can have many “faces”, clinicians should be aware of the great symptom variability among depressed patients and consider subforms when prescribing medication. In a sizeable amount of patients (up to 25%, Coryell et al., 1984), depression presents with [read the full story…]
During 2010/11 there were 1.53 million hospital admissions for illnesses directly attributable to smoking in the UK. These admissions, along with other smoking-related expenses, cost the NHS approximately £5 billion pounds per year. Fortunately, the NHS is spending £88.2 million per year on cessation treatments, many of which have been repeatedly demonstrated to be highly [read the full story…]
